NASDAQ:CDIO

Cardio Diagnostics Q4 2025 Earnings Results & Report

Cardio Diagnostics logo
$1.60 -0.05 (-3.03%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$1.60 -0.01 (-0.31%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cardio Diagnostics reported Q4 2025 earnings on March 13, 2026. The company reported EPS of -$0.80.

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
After Market Closes

Cardio Diagnostics EPS Results

Actual EPS
-$0.80
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 5 quarters

Cardio Diagnostics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Cardio Diagnostics Q4 2025 Earnings FAQ

Cardio Diagnostics (NASDAQ:CDIO) reported earnings of -$0.80 per share for Q4 2025. The report was announced on Friday, March 13, 2026.

Cardio Diagnostics Earnings Headlines

Whoops! I wasn’t supposed to share this with you yet
Traders have paid as much as $500 for technology like this. Thomas Wood of Base Camp Trading is offering his proprietary Snapback Indicator for just $7. There is no subscription and no recurring charge, and it's yours for life. The indicator is designed to help identify potential market turning points, showing when it may be time to buy, sell, or go short.tc pixel
See More Cardio Diagnostics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cardio Diagnostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cardio Diagnostics and other key companies, straight to your email.

About Cardio Diagnostics

Cardio Diagnostics (NASDAQ:CDIO) develops blood-based tests and technology for cardiovascular disease assessment. Its platform combines genetic and epigenetic information with artificial intelligence to support more personalized evaluation of heart disease.

The company’s offerings include Epi+Gen CHD, designed to assess a person’s risk of coronary heart disease, and PrecisionCHD, a test intended to help identify coronary heart disease in people being evaluated for the condition. The tests are designed to complement clinical assessment and are not a substitute for care from a health professional.

Founded in 2017 and based in Chicago, Illinois, Cardio Diagnostics was co-founded by Meesha Dogan, who serves as its chief executive officer. The company focuses primarily on making its testing services available in the United States.

View Cardio Diagnostics Profile